" class="no-js "lang="en-US"> ALS Archives - Medtech Alert
Saturday, December 07, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]

BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies

BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the […]

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced the completion of […]

Eikonoklastes Announces Formation of Scientific Advisory Board

Eikonoklastes Therapeutics, a biopharmaceutical company developing a novel gene therapy platform to discover and develop […]

Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS

The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval […]

Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients

Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device […]

ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment

ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment […]

NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced it has signed […]

Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS

Ionis has announced the outcome of the United States Food and Drug Administration’s (FDA) Peripheral […]

Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics, a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more